Clinical Trials Directory

Trials / Completed

CompletedNCT03211455

Intravenous Lidocaine in Bariatric Surgery.

Effect of Continuous Intravenous Lidocaine on Early Rehabilitation in Bariatric Surgery. A Randomized Double Blind Controlled Study

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
180 (actual)
Sponsor
University Hospital, Caen · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Although peroperative intravenous lidocaine has been shown to be useful in early recovery after colorectal surgery, its beneficial effect on the specific population of obese patients scheduled for bariatric surgery remained unknown. Investigators hypothesized that peroperative intravenous lidocaine could decrease postoperative opioid consumption and improve postoperative recovery

Detailed description

This is a prospective, double-blind, placebo-controlled, monocentric study. We plan to recruit 180 obese adult patients scheduled for bariatric surgery in a the french university hospital of Caen. Exclusion: contra-indications for any aminoamide local anesthetic (allergy, severe hepatic disease) and for intravenous lidocaine (porphyria, atrioventricular conduction disturbances, uncontrolled seizure disease), long term opioid consumption, need for a post-operative follow-up in an intensive care unit, combined surgical procedure excepting cholecystectomy, pregnancy. Patients will be randomly allocated to receive either a saline placebo or lidocaine continuous infusions during surgery. Morphinic consumption will be assessed from the end of the procedure until the third day after surgery. Secondary criteria will concern post-operative recovery, pain and postoperative nausea and vomiting, other medical and surgical complications, and toxicity. Plasma lidocaine concentrations will be measured in patients who had received lidocaine in order to determine the safety and efficiency of our infusion protocol. Our analysis will be a superiority one, alpha risk is 5% and beta risk is 20%, in intention to treat, with no intermediate analysis.

Conditions

Interventions

TypeNameDescription
DRUGLidocaineintravenous lidocaine versus placebo
DRUGisotonic salineintravenous isotonic saline

Timeline

Start date
2017-12-01
Primary completion
2019-02-01
Completion
2019-05-01
First posted
2017-07-07
Last updated
2026-02-17

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03211455. Inclusion in this directory is not an endorsement.